Persimmune

What Persimmune does

PersImmune is a privately held, clinical-stage immunotherapy company headquartered in San Diego, California. Its stated mission is to provide cancer patients with optimized immunotherapy, indicating a focus on developing or refining immune-based treatment regimens rather than a single product or modality. The company has been operating since its founding in 2009 and currently maintains a small team of 1-10 employees, consistent with an early-stage biotech that has not yet advanced to late-stage clinical development or commercialization.

The available source material does not disclose the specific therapeutic modality, pipeline assets, underlying platform technology, clinical trial status, or scientific founders and advisors. The company's website (persimmune.com) returned only a placeholder page with a privacy policy link and no substantive product, technology, or pipeline content. No funding rounds, partnerships, intellectual property filings, regulatory actions, management team details, or operating geographies are documented in the input data.

Because no revenue model, pricing structure, go-to-market motion, or customer segmentation is described, the business model cannot be characterized beyond the standard clinical-stage biotech framework: PersImmune presumably intends to develop its immunotherapy approach through preclinical and clinical stages, with eventual value realization via out-licensing, partnership with larger pharmaceutical companies, or independent commercialization. The absence of disclosed funding, partnerships, or trial milestones in the source data materially limits any deeper assessment of its commercial trajectory.

Name

Persimmune

Website

https://persimmune.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

PersImmune is a privately held, clinical-stage immunotherapy company based in San Diego, developing optimized immunotherapy treatments intended for cancer patients. Founded in 2009, it operates with a small team of 1-10 employees and has no disclosed commercial revenue.

Ownership category

akta.pro rank

Product category

Clinical-stage Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Cancer immunotherapy
• Clinical-stage biopharmaceuticals
• Oncology therapeutics
• Immunotherapy development
• Biological drug development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

PersImmune develops optimized immunotherapy treatments intended for cancer patients. Operating as a clinical-stage company, it focuses on advancing biological immunotherapeutic candidates through research and clinical development to provide oncology patients with improved treatment options.

Product overview

No product or service information available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Optimized Immunotherapy for Cancer

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Iovance Biotherapeutics: Clinical-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Directly comparable as a clinical-stage immunotherapy developer focused on optimizing cellular immune responses against cancer.
• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR cell therapies for solid tumors. Comparable as a personalized/optimized cancer immunotherapy company with similar modality and clinical-stage profile.
• Immatics: Clinical-stage immunotherapy company focused on TCR-based therapies and adoptive cell therapy for cancer. Comparable in targeting optimized, tumor-specific immune responses in oncology.
• Gritstone bio: Clinical-stage developer of personalized neoantigen cancer vaccines and immunotherapies. Directly comparable as a personalized cancer immunotherapy company aiming to optimize immune-driven tumor control.
• Fate Therapeutics: Clinical-stage cell therapy company developing iPSC-derived NK and T-cell immunotherapies for cancer. Comparable as a clinical-stage cancer immunotherapy developer with an 'off-the-shelf' optimization thesis.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer focused on cancer. Comparable as a clinical-stage company developing engineered cellular immunotherapies aimed at improving accessibility and efficacy.

Broad incumbents

• Moderna: Major mRNA biotechnology company with a clinical-stage cancer vaccine program (personalized neoantigen therapy). Comparable as a developer of individualized cancer immunotherapy, though vastly larger and broader in scope.
• BioNTech: Major mRNA immunotherapy company developing individualized neoantigen cancer vaccines. Comparable as a personalized cancer immunotherapy developer, though much larger, publicly traded, and with broader pipeline scope.
• Bristol-Myers Squibb: Large oncology incumbent with leading checkpoint inhibitor franchises (Opdivo, Yervoy) and active cell therapy business. Sets the competitive benchmark for cancer immunotherapy and is a likely strategic acquirer or partner for clinical-stage developers.
• Merck & Co. Global oncology leader with Keytruda (pembrolizumab), the dominant checkpoint immunotherapy. Defines the standard of care that PersImmune's 'optimized immunotherapy' would need to improve upon, and represents a likely large-pharma partner or acquirer.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/persimmune
• LinkedInlinkedin.com/company/persimmune

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Persimmune